Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 72 | 2024 | 5753 | 4.420 |
Why?
|
Graft vs Host Disease | 41 | 2024 | 3078 | 3.000 |
Why?
|
Epstein-Barr Virus Infections | 10 | 2024 | 617 | 2.740 |
Why?
|
Lymphoproliferative Disorders | 6 | 2024 | 526 | 2.140 |
Why?
|
Cytomegalovirus Infections | 7 | 2024 | 836 | 2.020 |
Why?
|
Transplantation Conditioning | 25 | 2024 | 1635 | 1.590 |
Why?
|
Severe Combined Immunodeficiency | 10 | 2024 | 235 | 1.540 |
Why?
|
Transplantation, Homologous | 33 | 2024 | 4860 | 1.490 |
Why?
|
Cytomegalovirus | 6 | 2024 | 751 | 1.480 |
Why?
|
Herpesvirus 4, Human | 8 | 2024 | 1078 | 1.260 |
Why?
|
Adoptive Transfer | 5 | 2022 | 827 | 1.230 |
Why?
|
T-Lymphocytes | 28 | 2024 | 10261 | 1.110 |
Why?
|
Lymphocyte Depletion | 8 | 2020 | 605 | 1.050 |
Why?
|
Immunotherapy, Adoptive | 8 | 2024 | 1510 | 0.940 |
Why?
|
Organ Transplantation | 4 | 2024 | 1174 | 0.930 |
Why?
|
Leukemia | 5 | 2024 | 1522 | 0.920 |
Why?
|
Acetates | 1 | 2024 | 313 | 0.820 |
Why?
|
Transplants | 1 | 2022 | 208 | 0.660 |
Why?
|
Thymus Gland | 6 | 2004 | 1261 | 0.650 |
Why?
|
Quinazolines | 1 | 2024 | 1364 | 0.580 |
Why?
|
Leukemia, Myeloid, Acute | 9 | 2023 | 3646 | 0.570 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 1560 | 0.530 |
Why?
|
beta-Thalassemia | 5 | 2024 | 233 | 0.530 |
Why?
|
Busulfan | 6 | 2024 | 264 | 0.530 |
Why?
|
Lymphoma | 4 | 2024 | 1897 | 0.530 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2020 | 266 | 0.510 |
Why?
|
Antiviral Agents | 4 | 2024 | 3050 | 0.480 |
Why?
|
Viremia | 5 | 2023 | 727 | 0.470 |
Why?
|
Fanconi Anemia | 4 | 2023 | 327 | 0.460 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2015 | 316 | 0.430 |
Why?
|
Hematologic Neoplasms | 7 | 2023 | 1927 | 0.430 |
Why?
|
Antilymphocyte Serum | 6 | 2024 | 493 | 0.430 |
Why?
|
Granulomatous Disease, Chronic | 2 | 2024 | 176 | 0.410 |
Why?
|
T-Lymphocytes, Cytotoxic | 6 | 2021 | 1801 | 0.400 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2226 | 0.400 |
Why?
|
Myelodysplastic Syndromes | 6 | 2024 | 1404 | 0.390 |
Why?
|
Mesenchymal Stem Cell Transplantation | 4 | 2020 | 504 | 0.390 |
Why?
|
Hematopoietic Stem Cells | 8 | 2024 | 3401 | 0.380 |
Why?
|
Myeloablative Agonists | 6 | 2020 | 215 | 0.370 |
Why?
|
Child | 52 | 2024 | 80564 | 0.330 |
Why?
|
Vidarabine | 5 | 2018 | 343 | 0.330 |
Why?
|
Histocompatibility Testing | 6 | 2019 | 726 | 0.310 |
Why?
|
Virus Diseases | 3 | 2022 | 718 | 0.310 |
Why?
|
Adenoviridae Infections | 2 | 2020 | 97 | 0.310 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2022 | 4405 | 0.300 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 962 | 0.290 |
Why?
|
Humans | 107 | 2025 | 765968 | 0.290 |
Why?
|
Tissue Donors | 7 | 2024 | 2395 | 0.280 |
Why?
|
T-Lymphocyte Subsets | 3 | 2004 | 1811 | 0.270 |
Why?
|
Kidney Transplantation | 1 | 2022 | 4270 | 0.270 |
Why?
|
Acute Disease | 10 | 2024 | 7232 | 0.260 |
Why?
|
Child, Preschool | 35 | 2025 | 42500 | 0.260 |
Why?
|
Microtubule-Organizing Center | 1 | 2025 | 26 | 0.240 |
Why?
|
Hemoglobinopathies | 2 | 2024 | 101 | 0.240 |
Why?
|
Cyclophosphamide | 4 | 2023 | 2228 | 0.230 |
Why?
|
Chimerism | 3 | 2021 | 154 | 0.230 |
Why?
|
Receptors, Interferon | 1 | 2024 | 114 | 0.220 |
Why?
|
Viral Matrix Proteins | 2 | 2015 | 192 | 0.220 |
Why?
|
Antigens, Viral | 2 | 2019 | 995 | 0.220 |
Why?
|
Candidiasis, Chronic Mucocutaneous | 1 | 2023 | 19 | 0.220 |
Why?
|
Mesenchymal Stem Cells | 3 | 2020 | 1663 | 0.210 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2024 | 2570 | 0.210 |
Why?
|
Golgi Apparatus | 1 | 2025 | 405 | 0.210 |
Why?
|
Interleukin Receptor Common gamma Subunit | 2 | 2018 | 89 | 0.210 |
Why?
|
Infant | 25 | 2024 | 36386 | 0.210 |
Why?
|
Janus Kinase 3 | 2 | 2018 | 75 | 0.200 |
Why?
|
Recurrence | 4 | 2024 | 8501 | 0.200 |
Why?
|
Integrins | 2 | 2004 | 840 | 0.200 |
Why?
|
Cell Movement | 4 | 2003 | 5194 | 0.190 |
Why?
|
Young Adult | 27 | 2024 | 59889 | 0.190 |
Why?
|
Lymphopenia | 1 | 2024 | 297 | 0.190 |
Why?
|
Transplantation, Autologous | 2 | 2024 | 2120 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2022 | 312 | 0.180 |
Why?
|
Hemoglobinuria, Paroxysmal | 2 | 2011 | 86 | 0.180 |
Why?
|
Globins | 1 | 2022 | 406 | 0.180 |
Why?
|
Agammaglobulinemia | 1 | 2022 | 173 | 0.180 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Antigens, CD34 | 5 | 2022 | 656 | 0.180 |
Why?
|
Retrospective Studies | 28 | 2024 | 81514 | 0.180 |
Why?
|
Disease-Free Survival | 7 | 2020 | 6832 | 0.170 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2022 | 249 | 0.170 |
Why?
|
Adenylate Kinase | 1 | 2020 | 100 | 0.170 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2020 | 131 | 0.170 |
Why?
|
Adolescent | 36 | 2024 | 88835 | 0.170 |
Why?
|
Leukopenia | 1 | 2020 | 213 | 0.160 |
Why?
|
Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 163 | 0.160 |
Why?
|
Cadherins | 1 | 2004 | 900 | 0.160 |
Why?
|
Male | 51 | 2025 | 363698 | 0.160 |
Why?
|
Adult | 38 | 2024 | 223044 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9373 | 0.160 |
Why?
|
Lentivirus | 1 | 2022 | 518 | 0.160 |
Why?
|
Salvage Therapy | 3 | 2019 | 1272 | 0.150 |
Why?
|
Bone Marrow Cells | 2 | 2023 | 2412 | 0.150 |
Why?
|
Bone Marrow Transplantation | 3 | 2018 | 2729 | 0.150 |
Why?
|
Extracellular Matrix Proteins | 1 | 2002 | 833 | 0.150 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1009 | 0.150 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 230 | 0.150 |
Why?
|
Alleles | 3 | 2024 | 6897 | 0.140 |
Why?
|
Standard of Care | 1 | 2022 | 567 | 0.140 |
Why?
|
Introns | 1 | 2020 | 966 | 0.140 |
Why?
|
Female | 46 | 2025 | 396112 | 0.140 |
Why?
|
Heterozygote | 1 | 2024 | 2794 | 0.140 |
Why?
|
Survival Rate | 7 | 2020 | 12795 | 0.140 |
Why?
|
Gene Transfer Techniques | 2 | 2014 | 1216 | 0.140 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1067 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2019 | 443 | 0.130 |
Why?
|
Hematologic Diseases | 2 | 2020 | 500 | 0.130 |
Why?
|
Anemia, Aplastic | 1 | 2018 | 232 | 0.130 |
Why?
|
Phosphoproteins | 2 | 2015 | 2446 | 0.130 |
Why?
|
HLA Antigens | 4 | 2016 | 1339 | 0.130 |
Why?
|
Treatment Outcome | 16 | 2024 | 65188 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 616 | 0.120 |
Why?
|
Mycophenolic Acid | 2 | 2015 | 346 | 0.120 |
Why?
|
Killer Cells, Natural | 1 | 2025 | 2210 | 0.120 |
Why?
|
Genetic Vectors | 3 | 2022 | 3404 | 0.120 |
Why?
|
Survival Analysis | 10 | 2020 | 10070 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 1434 | 0.120 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2015 | 57 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2587 | 0.120 |
Why?
|
Lymphocyte Transfusion | 1 | 2015 | 236 | 0.110 |
Why?
|
Neoplasms | 1 | 2023 | 22340 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 915 | 0.110 |
Why?
|
Neonatal Screening | 3 | 2024 | 627 | 0.110 |
Why?
|
Lung Diseases | 1 | 2024 | 1940 | 0.110 |
Why?
|
beta-Globins | 1 | 2014 | 112 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.110 |
Why?
|
Interleukins | 1 | 2018 | 791 | 0.110 |
Why?
|
Skin Diseases | 1 | 2021 | 1088 | 0.100 |
Why?
|
Remission Induction | 2 | 2016 | 2411 | 0.100 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2014 | 227 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4642 | 0.100 |
Why?
|
Dyskeratosis Congenita | 1 | 2012 | 70 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5337 | 0.100 |
Why?
|
Cell Differentiation | 7 | 2018 | 11641 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2017 | 866 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2024 | 2159 | 0.100 |
Why?
|
Transplantation Chimera | 2 | 2004 | 609 | 0.090 |
Why?
|
Chickenpox Vaccine | 1 | 2011 | 39 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2022 | 2968 | 0.090 |
Why?
|
Meningococcal Infections | 1 | 2011 | 78 | 0.090 |
Why?
|
Meningococcal Vaccines | 1 | 2011 | 96 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2741 | 0.090 |
Why?
|
Keratinocytes | 1 | 2015 | 863 | 0.090 |
Why?
|
Exanthema | 1 | 2015 | 502 | 0.090 |
Why?
|
Infant, Newborn | 8 | 2024 | 26346 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 385 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 614 | 0.090 |
Why?
|
Herpesvirus 3, Human | 1 | 2011 | 159 | 0.090 |
Why?
|
B-Lymphocytes | 3 | 2025 | 4778 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1383 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11868 | 0.080 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 330 | 0.080 |
Why?
|
Mutation | 5 | 2025 | 30198 | 0.080 |
Why?
|
Melphalan | 3 | 2017 | 425 | 0.080 |
Why?
|
Animals, Newborn | 2 | 2004 | 2669 | 0.070 |
Why?
|
Lymphocyte Count | 2 | 2022 | 790 | 0.070 |
Why?
|
Prognosis | 5 | 2020 | 29922 | 0.070 |
Why?
|
Radiation Chimera | 2 | 2004 | 216 | 0.070 |
Why?
|
Mice | 8 | 2023 | 81819 | 0.070 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2025 | 1347 | 0.070 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 834 | 0.070 |
Why?
|
Middle Aged | 18 | 2024 | 223009 | 0.070 |
Why?
|
Immunization | 2 | 2011 | 1219 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3111 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1376 | 0.060 |
Why?
|
Tissue Plasminogen Activator | 1 | 2011 | 1167 | 0.060 |
Why?
|
Canada | 2 | 2023 | 2119 | 0.060 |
Why?
|
Transduction, Genetic | 2 | 2022 | 898 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 2817 | 0.060 |
Why?
|
Animals | 12 | 2023 | 168764 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 1731 | 0.060 |
Why?
|
Hepatitis B Vaccines | 1 | 2006 | 178 | 0.060 |
Why?
|
Cell Division | 2 | 2004 | 4475 | 0.060 |
Why?
|
Genetic Variation | 1 | 2020 | 6610 | 0.060 |
Why?
|
Inflammation | 1 | 2025 | 10850 | 0.060 |
Why?
|
Cell Adhesion | 2 | 2002 | 3089 | 0.060 |
Why?
|
Lymphocytes, Null | 1 | 2004 | 13 | 0.060 |
Why?
|
Animals, Congenic | 1 | 2004 | 27 | 0.060 |
Why?
|
Thymus Extracts | 1 | 2004 | 2 | 0.060 |
Why?
|
Adenoviridae | 2 | 2020 | 1092 | 0.060 |
Why?
|
Steroids | 2 | 2020 | 933 | 0.060 |
Why?
|
Receptors, Interleukin-7 | 1 | 2004 | 41 | 0.060 |
Why?
|
Homeodomain Proteins | 2 | 2025 | 2428 | 0.060 |
Why?
|
Aged | 12 | 2024 | 171117 | 0.060 |
Why?
|
Viral Load | 3 | 2020 | 3386 | 0.060 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2004 | 220 | 0.060 |
Why?
|
Bone Marrow | 3 | 2024 | 2921 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7851 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1050 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2011 | 1171 | 0.050 |
Why?
|
Peptides | 1 | 2015 | 4331 | 0.050 |
Why?
|
Injections, Intralymphatic | 1 | 2002 | 15 | 0.050 |
Why?
|
Stromal Cells | 3 | 2003 | 1329 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12509 | 0.050 |
Why?
|
Thrombolytic Therapy | 1 | 2011 | 2059 | 0.050 |
Why?
|
Cytoplasmic Granules | 1 | 2025 | 574 | 0.050 |
Why?
|
Adrenoleukodystrophy | 1 | 2024 | 147 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2011 | 2080 | 0.050 |
Why?
|
STAT1 Transcription Factor | 1 | 2023 | 339 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6499 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2004 | 839 | 0.050 |
Why?
|
Immunodominant Epitopes | 1 | 2022 | 244 | 0.050 |
Why?
|
Immunosuppressive Agents | 3 | 2011 | 4209 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2004 | 1524 | 0.040 |
Why?
|
Adenosine Deaminase | 1 | 2022 | 251 | 0.040 |
Why?
|
North America | 1 | 2024 | 1285 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 694 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 633 | 0.040 |
Why?
|
Prospective Studies | 6 | 2023 | 54802 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 357 | 0.040 |
Why?
|
Organ Size | 1 | 2004 | 2260 | 0.040 |
Why?
|
Mice, SCID | 1 | 2004 | 2630 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2004 | 14448 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2003 | 728 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2004 | 2060 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8041 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18071 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 894 | 0.040 |
Why?
|
Models, Immunological | 1 | 2000 | 517 | 0.040 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9249 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2004 | 22332 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2022 | 1043 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39193 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2025 | 9601 | 0.030 |
Why?
|
Graft Survival | 3 | 2018 | 3890 | 0.030 |
Why?
|
Europe | 1 | 2024 | 3423 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 13024 | 0.030 |
Why?
|
Thiotepa | 1 | 2016 | 66 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9347 | 0.030 |
Why?
|
Arabinonucleosides | 1 | 2016 | 35 | 0.030 |
Why?
|
Adenine Nucleotides | 1 | 2016 | 110 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2523 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3797 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2019 | 302 | 0.030 |
Why?
|
RNA Splicing | 1 | 2020 | 903 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15880 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2021 | 1966 | 0.030 |
Why?
|
Blood Banks | 1 | 2016 | 108 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 644 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2016 | 438 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2004 | 2423 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2022 | 1297 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2004 | 5881 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2004 | 9550 | 0.030 |
Why?
|
Phenotype | 2 | 2025 | 16721 | 0.030 |
Why?
|
Immunotherapy | 1 | 2010 | 4752 | 0.030 |
Why?
|
Exons | 1 | 2020 | 2391 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 10729 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2018 | 605 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 256 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1789 | 0.030 |
Why?
|
Antigens, CD | 1 | 2004 | 4025 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2014 | 351 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 199 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3344 | 0.030 |
Why?
|
Cell Communication | 1 | 2000 | 1660 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 2010 | 0.030 |
Why?
|
Erythroid Precursor Cells | 1 | 2014 | 211 | 0.030 |
Why?
|
Kinetics | 1 | 2020 | 6274 | 0.030 |
Why?
|
Homeostasis | 2 | 2001 | 3336 | 0.030 |
Why?
|
Siblings | 1 | 2017 | 828 | 0.030 |
Why?
|
Trans-Activators | 1 | 2022 | 2850 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 21480 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2796 | 0.020 |
Why?
|
Protein Binding | 1 | 2004 | 9296 | 0.020 |
Why?
|
Calcineurin | 1 | 2013 | 233 | 0.020 |
Why?
|
Budesonide | 1 | 2013 | 163 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4108 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2014 | 700 | 0.020 |
Why?
|
Plant Lectins | 1 | 2011 | 103 | 0.020 |
Why?
|
Soybean Proteins | 1 | 2011 | 55 | 0.020 |
Why?
|
Stem Cells | 1 | 2004 | 3540 | 0.020 |
Why?
|
Rabbits | 1 | 2017 | 4734 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1617 | 0.020 |
Why?
|
Immunoglobulin Joining Region | 1 | 1990 | 37 | 0.020 |
Why?
|
Antibody Diversity | 1 | 1990 | 71 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15747 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2025 | 5783 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2229 | 0.020 |
Why?
|
Vaccines, Attenuated | 1 | 2011 | 312 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2535 | 0.020 |
Why?
|
Hemolysis | 1 | 2011 | 406 | 0.020 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1990 | 177 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 1990 | 285 | 0.020 |
Why?
|
Immunoglobulin Variable Region | 1 | 1990 | 419 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2004 | 18973 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5929 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10429 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4499 | 0.020 |
Why?
|
Time Factors | 3 | 2016 | 40065 | 0.020 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2007 | 13 | 0.020 |
Why?
|
Skin | 1 | 2021 | 4489 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8297 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5501 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2011 | 1831 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12056 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14751 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 2505 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2011 | 1476 | 0.020 |
Why?
|
DNA, Viral | 1 | 2011 | 2199 | 0.010 |
Why?
|
Cohort Studies | 2 | 2020 | 41649 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1880 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 691 | 0.010 |
Why?
|
Tacrolimus | 1 | 2007 | 753 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6069 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3715 | 0.010 |
Why?
|
Keratins | 1 | 2003 | 498 | 0.010 |
Why?
|
Anemia | 1 | 2011 | 1511 | 0.010 |
Why?
|
Lymphocytes | 1 | 1990 | 2599 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2011 | 1327 | 0.010 |
Why?
|
Chemokines, CXC | 1 | 2003 | 416 | 0.010 |
Why?
|
Neutrophils | 1 | 2014 | 3776 | 0.010 |
Why?
|
United States | 2 | 2021 | 72903 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2003 | 455 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7584 | 0.010 |
Why?
|
Receptors, Chemokine | 1 | 2003 | 651 | 0.010 |
Why?
|
Signal Transduction | 1 | 2003 | 23601 | 0.010 |
Why?
|
Methotrexate | 1 | 2007 | 1722 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2011 | 4528 | 0.010 |
Why?
|
Thrombosis | 1 | 2011 | 2949 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 6309 | 0.010 |
Why?
|
Anticoagulants | 1 | 2011 | 4862 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24282 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18293 | 0.010 |
Why?
|
Risk Factors | 2 | 2011 | 74840 | 0.010 |
Why?
|
Hematopoiesis | 1 | 2001 | 2058 | 0.010 |
Why?
|
VDJ Recombinases | 1 | 1990 | 84 | 0.010 |
Why?
|
Pregnancy | 1 | 2011 | 30260 | 0.010 |
Why?
|
Clone Cells | 1 | 1990 | 1672 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2011 | 59489 | 0.000 |
Why?
|
Gene Rearrangement | 1 | 1990 | 1144 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2006 | 13648 | 0.000 |
Why?
|
Cell Line | 1 | 1990 | 15543 | 0.000 |
Why?
|